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Abstract 
Two major difficulties facing widespread clinical implementation of existing Tissue Engineering (TE) 
strategies for the treatment of musculoskeletal disorders are (1) the cost, space and time required for ex 
vivo culture of a patient’s autologous cells prior to re-implantation as part of a TE construct, and (2) the 
potential risks and availability constraints associated with transplanting exogenous (foreign) cells. These 
hurdles have led to recent interest in endogenous TE strategies, in which the regenerative potential of a 
patient’s own cells is harnessed to promote tissue regrowth without ex vivo cell culture. This article 
provides a focused perspective on key issues in the development of endogenous TE strategies, progress 
to date, and suggested future research directions toward endogenous repair and regeneration of 
musculoskeletal tissues and organs. 
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Introduction 
Diseases and disorders of the musculoskeletal system occur at all stages of life. During childhood and 
adolescence, deformities during skeletal growth can arise due to genetic defects, infectious disease, and 
other growth imbalances1,2. In adulthood, osteoarthritis and back pain are major contributors to 
immobility, pain, and lost productivity3,4. In the elderly, skeletal thinning due to osteoporosis causes 
increased susceptibility to fracture5. At all ages, cancer, trauma and infectious diseases can lead to large 
scale bone, joint and soft tissue destruction6,7,8. 
Musculoskeletal disorders are a major cause of disability worldwide. In the United States, 
musculoskeletal diseases are reported more than any other health condition. In 2004, the estimated 
direct cost of treatment for musculoskeletal conditions in the US was $510 billion, with a further $339 
billion in indirect costs, in total comprising 7.7 percent of Gross Domestic Product9. Table 1 below shows 
the estimated global burden of musculoskeletal disease in 2001, comprising just under 30 million 
Disability Adjusted Life Years (DALYs), of which 21 million DALYS were in developing countries, and nine 
million were in developed countries. It is important to note that the already high proportion of 
musculoskeletal disease in developing regions is expected to grow further due to rapidly increasing life 
expectancy in these countries. Note also that the data in Table 1 do not include osteoporotic fractures, 
which are separately classified10. 
 
Table 1. Global burden of musculoskeletal disease in 2001 (DALYS = Disability Adjusted Life Years)10 
Condition Developing countries 
(DALYS) 
Developed countries 
(DALYS) 
Total 
(DALYS) 
Rheumatoid arthritis 3,238,000 1,520,000 4,757,000 
Osteoarthritis 11,049,000 5,323,000 16,372,000 
Other musculoskeletal 
diseases 
6,789,000 1,880,000 8,699,000 
All musculoskeletal diseases 21,076,000 8,723,000 29,798,000 
 
 
Derived from the embryonic mesoderm, the human musculoskeletal system is a complex structure of 
bones and joints connected by ligaments. Articulating movement between adjacent bones occurs 
between the smooth sliding surfaces of articular cartilage, and the muscles which power movement are 
attached to bone via tough, flexible tendons. The role of the musculoskeletal system is predominantly 
mechanical, exerting and withstanding the forces associated with physical function and mobility. It 
follows that each of the tissues in the musculoskeletal system are highly adapted to a particular 
mechanical role. Bone achieves lightweight stiffness and strength (fracture resistance) using a 
hierarchical assembly of mineralised collagen fibres, built from the nanoscale up11. Ligaments are tough, 
collagenous tension-bearing structures with non-linear force versus stretch characteristics, and low 
elastic energy storage capacity12. Articular cartilage is comprised of graduated zones of collagen fibre 
network pre-strained by the physico-chemical swelling of hydrophilic proteoglycan molecules within the 
network13. Skeletal muscle is comprised of a repeated hierarchical assembly of actin and myosin fibres 
again held in place by a collagen network (the endomysium)14. The intervertebral discs of the spine are 
the largest avascular structures in the body, resisting forces of up to nine times bodyweight during 
strenuous activity, and are comprised of a series of annular rings of collagenous fibres criss-crossed in 
alternating orientations, surrounding a jelly-like inner nucleus which is pressurised within the annular 
outer layers15. Tendon is a tough and resilient parallel-fibred collagenous tissue which allows 
transmission of high forces from muscles to their bony attachment points16. 
The defining characteristic of the musculoskeletal tissues is their primary load-bearing function, which 
structurally requires a dense, tough extra-cellular matrix (ECM) comprised of hierarchically assembled 
fibrous proteins. These ECM structures are built and maintained by a network of living cells both on and 
within the ECM. Cell activity is in turn controlled by soluble signalling molecules, as well as by signals 
from the ECM itself, so that the ECM acts as both a substrate for cell attachment and a chemical and 
mechanical signalling source to control cell activity17. Within this general framework, musculoskeletal 
tissues exhibit a diverse range of morphologies and mechanical properties specifically adapted for their 
structural role. 
The individual tissues of the musculoskeletal system exhibit a strong ability to adapt their composition 
and structure in response to alterations in external loading conditions. For example, it is well known that 
rapid bone loss occurs during extended bed rest, space flight, or on a local scale adjacent to a stiff, 
metallic load bearing implant after surgical implantation18,19,20,21. The mechanobiological response of 
musculoskeletal tissues strengthens them (hypertrophy) in response to increased loading, and removes 
tissue (atrophy) in response to reduced loading. This remodelling ability is successful in adapting the 
musculoskeletal system to altering demands throughout life, and there is strong evidence that 
remodelling in both mineralised and soft tissues is induced in response to microscope damage of the 
ECM22. 
In the case of large scale macroscopic insult to a musculoskeletal organ however, repair is not 
guaranteed, and there is a limit to the size of defect which the body can spontaneously repair. The 
concept of the critical sized bone defect was introduced by Schmitz & Hollinger in 198623, defined as the 
smallest defect which will not spontaneously heal. Similarly in non-mineralised musculoskeletal tissues 
such as cartilage and intervertebral disc, focal defects of a given size lead to further degeneration (and 
eventual complete destruction of the organ in question) rather than spontaneous repair24,25. These 
critical sized defects are a key target of Tissue Engineering strategies for musculoskeletal regeneration. 
We note however that Cooper et al26 have recently recommended that the term “critical size defect” be 
discontinued due to the difficulties surrounding the clinical applicability of the concept. 
The overarching goal of the rapidly developing fields of Tissue Engineering (TE) and Regenerative 
Medicine is the controlled growth of new tissues to replace diseased, damaged and degenerate native 
tissues and organs. Continuing interest in tissue regeneration has been driven by the promising 
outcomes of research in the field to date, combined with strong growth in clinical demand due to 
increasing numbers of patients surviving severe trauma, burns, cancer, degeneration and chronic 
disease, treatments for which often require replacement of lost or damaged tissue. 
Research in musculoskeletal TE to date has yielded genuine advances in harnessing the regenerative 
ability of precursor cells when seeded on biomaterial scaffolds together with growth factors in 
musculoskeletal defects, demonstrating that clinically significant results can be achieved27. However, 
major challenges remain in the development of effective TE approaches suitable for widespread clinical 
use. In particular, there are key difficulties around (i) the requirement for multiple surgical procedures if 
autologous cells are harvested, expanded ex vivo and then re-implanted later, (ii) the cost, space and 
time required for ex vivo culture of a patient’s own cells, and (iii) the risks associated with implanting 
exogenous progenitor cells. Logistical concerns are particularly important given the high burden of 
musculoskeletal disease in developing countries (Table 1), therefore treatments should be simple, 
effective, and as economical as possible. 
For these reasons, endogenous approaches to tissue regeneration have been proposed. These 
approaches are attractive in principle, because they do not require ex vivo cell culture, require only a 
single surgical procedure, and do not involve exogenous cell implantation, thus potentially avoiding key 
barriers to clinical adoption. In the context of Tissue Engineering approaches, recent work has 
demonstrated exciting possibilities for the regeneration of load-bearing musculoskeletal tissues by 
endogenous cells guided by synthetic scaffolds28, but there is much further work to be done in 
elucidating the interaction between cells, host extra-cellular matrix, signalling molecules, and 
biomaterial scaffolds to effectively facilitate endogenous cell migration and repair of a defect site. With 
this in mind, the aim of this paper is to highlight emerging approaches to endogenous Tissue Engineering 
of the musculoskeletal system and discuss current progress, challenges and future research directions. 
The overview given here is not intended to be an exhaustive review, but to provide an introduction to 
key issues in this newly emerging area of research. 
Definition and classification of endogenous TE strategies 
We define the term ‘endogenous’ from the perspective of the origin of all cells involved in the 
regeneration process. From the perspective of cell origin, all cells involved in regenerating the damaged 
or diseased tissue must be endogenous to the patient. We note that others have suggested a broader 
definition which would include ex vivo cultured autologous cells29, however because it is known that ex 
vivo culture changes cellular signalling responses30, and due to the aforementioned cost and time 
barriers associated with ex vivo culture, we use the term ‘endogenous’ in its strict sense. Note also that 
this nomenclature does not preclude the use of exogenous synthetic scaffolds or exogenous signalling 
molecules, so long as all cells are endogenous to the patient. It follows that progenitor cells which 
populate the defect site must come from one of three possible sources; (i) auto-transplantation from 
another anatomical site at the time of surgery, (ii) via cell homing from the bloodstream or neighbouring 
tissues, or (iii) via de-differentiation of committed cells at the defect site. Each of these possibilities is 
discussed further below, and Table 2 identifies these three possible endogenous TE strategies within the 
broader spectrum of TE strategies. For an overview of endogenous approaches to regenerative medicine 
(including, but not limited to, musculoskeletal applications) the reader is directed to several recent 
review papers29,31-34. Our focus here is specifically on Tissue Engineering strategies in which a biomaterial 
scaffold assists and modulates endogenous cells to regenerate load bearing musculoskeletal tissues. 
 
Table 2. Classification of TE strategies according to cell source, signalling molecule source, and scaffold 
source. The three endogenous strategies (from a cellular perspective) are highlighted in grey. 
 
In this schema, it is possible to define a particular TE strategy in terms of its cell (C), growth factor (G), 
and scaffold source (S), for example C2G1S1. Then according to the definition given above, there are 18 
possible ‘endogenous’ strategies (i.e. C1GxSx , C2GxSx and C3GxSx) from a cellular perspective, even though 
 
Cell 
source(C) 
C1: Endogenous 
(autotransplantation) 
C2: 
Endogenous 
(homing) 
C3 : 
Endogenous 
(de-
differentiation) 
C3: Expanded 
autologous C4: Exogenous 
Progenitor cells 
transplanted from 
other anatomical sites 
(e.g. bone marrow, 
fat, muscle biopsy - 
MSCs, adipose-
derived stromal cells) 
Cell migration 
from bone 
marrow via 
bloodstream, or 
from 
neighbouring 
tissue niche 
Previously 
committed 
cells induced to 
de-
differentiate. 
Mammalian 
skeletal 
capacity 
unknown? 
Autologous 
cells expanded 
via ex vivo 
culture (e.g. 
Autologous 
Chondrocyte 
Implantation) 
Cells derived 
from sources 
external to the 
patient (e.g. cord-
derived 
mesenchymal 
stem cells, 
embryonic stem 
cells) 
Growth 
factor 
source (G) 
G1: Endogenous G2: Exogenous 
e.g. platelet derived growth factor (PDGF) from autologous 
blood 
e.g. recombinant human bone 
morphogenetic protein-2 (rhBMP-
2) 
Scaffold 
source (S) 
S1: Endogenous tissue scaffold S2: Exogenous 
tissue scaffold 
S3: Synthetic 
scaffold 
e.g. fibrin clot, autologous bone graft e.g. allogeneic 
bone graft, 
xenograft 
bone 
e.g. 
polycaprolactone 
+ tricalcium 
phosphate 
exogenous scaffolds or growth factors may be involved. The C4GxSx and C5GxSx groups of strategies 
represent the widely used TE approaches involving cultured autologous cells, and exogenous cells 
respectively, on which the majority of research attention has been focussed to date. 
 
Regenerative biology and the potential for cellular de-differentiation 
The defining characteristic of an endogenous TE strategy as defined above is that the patient’s own 
stem/progenitor cells must either be attracted to, auto-transplanted to, or de-differentiated at, the 
regeneration site. Furthermore, the biochemical and biophysical micro-environment in the regeneration 
site must promote appropriate processes of epimorphic cellular proliferation, differentiation, and ECM 
synthesis to facilitate the controlled regeneration of viable, vascularised tissue. Valuable lessons can be 
learnt in this regard by considering the native regenerative potential of the mature vertebrate 
musculoskeletal system as studied in the field of regenerative biology35. Gillers has pointed out that 
existing studies on limb regeneration have received little attention in the TE literature to date36. 
Urodeles such as newts and salamanders have the capacity to spontaneously regenerate lost body parts 
and injured organs. Following limb amputation, various cell types (including connective tissue cells) de-
differentiate and migrate to form a mass of undifferentiated cells (blastema) at the end of the stump. 
The key aspect of this regenerative ability is the de-differentiation of fully differentiated cells in the 
wound region, followed by proliferation and re-differentiation into the appropriate cell types for 
regeneration37-40. The signalling pathways that control this regeneration process are not fully known, 
however it appears that they only invoke embryonic organogenesis pathways to a limited extent41, and 
various signalling molecules have been identified during limb regeneration. For example, Maden42 has 
discussed the importance of retinoids (vitamin A derivatives) in limb and tail regeneration, such that in 
cases where retinoic acid synthesis is inhibited, limb and tail regenerative ability is inhibited as well. 
Kumar et al43 have shown how the nerve dependence of limb regeneration (denervated limbs do not 
spontaneously regenerate) is related to expression of the anterior gradient protein nAG in the 
regenerating nerve. nAG is a growth factor for blastemal cells and a ligand for the surface protein Prod 1. 
The regenerative capacity of mammals is much less than that of Urodeles however. Mammals (including 
humans) have the ability to repair small defects and regions of damaged tissue, but are not able to 
spontaneously repair large tissue defects. This difference seems to be mainly related to the ability of 
amphibians such as salamanders to produce progenitor cells by de-differentiation of differentiated cells 
back to precursor cells, whereas mammalian regeneration relies on recruitment of existing progenitor 
cells. Against this background of the limited innate regenerative capacity of mammals, what is the 
potential of endogenous strategies to enhance the regenerative ability of the human musculoskeletal 
system? 
Firstly, several key studies appear to show that mammalian myotubes44 and cardiomyocytes45 can be 
induced to de-differentiate, proliferate, and re-differentiate into adipocytes, chondrocytes, and 
osteogenic cells. This work was subsequently extended to demonstrate therapeutic regeneration of rat 
hearts following surgically induced myocardial infarction using FGF1/p38 MAP kinase inhibitor therapy46. 
A significant focus of attention with regard to mammalian regeneration is the MRL mouse, which 
demonstrates exceptional healing ability in an ear punch wound model47, and has also been claimed to 
demonstrate myocardial regenerative ability. However a recent study compared infarct sizes, levels of 
fibrosis, and subsequent cardiac function between MRL and C57BL/6 mice and found no difference 
between the two strains48. To the author’s knowledge there are no studies of regeneration in mammals 
invoking de-differentiation, proliferation and re-differentiation of mammalian bone, joint or skeletal 
muscle cells as was achieved for the rat cardiac muscle study described above. However the rat 
myocardial infarction results indicate a potentially beneficial and so far unexplored potential research 
direction for de-differentiation based strategies in musculoskeletal regeneration. 
 
Auto-transplantation and homing of endogenous cells 
Another option for delivering cells to the defect site is auto-transplantation. Several clinical studies have 
demonstrated the healing ability of bone marrow aspirate re-injected percutaneously into fracture non-
unions49,50. In a related approach, the ‘microfracture’ technique for cartilage regeneration51,52 uses 
perforations of the subchondral bone to enable localised transport of marrow and blood into contact 
with degenerate cartilagea. Fong et al53 have discussed the logistical difficulties associated with direct 
marrow transplantation approaches, pointing out that only 7-10 MSCs per million mono-nucleated cells 
can be isolated from bone marrow aspirates, therefore several millilitres of bone marrow would yield 
less than 100 MSCs51,53. Hernigou et al54 found that concentrating bone marrow aspirate to increase cell 
density improved the healing rate when treating tibial non-unions, and suggested that a cell 
density >1000 cells/cm3 was required, which is substantially higher than the 600 cells/cm3 found in un-
concentrated iliac crest bone marrow53. 
Aside from MSCs in bone marrow, progenitor cells have been reported in other tissues55. For instance, 
Jackson et al56 report multipotent cells (MPCs) in traumatically injured muscle tissue capable of 
differentiation into osteoblasts, adipocytes and chondrocytes, but with limited lineage commitment 
compared to bone marrow derived MSCs. The MPCs also demonstrated trophic (immunoregulatory and 
pro-angiogenic) properties comparable to MSCs. The authors suggest that the ready availability of these 
cells following orthopaedic injuries (involving traumatized muscle tissue) makes them an attractive 
possible cell source for regenerative medicine approaches. Adipose tissues also provide a readily 
available source of stromal cells, and adipose derived stromal cells have been used to successfully 
regenerate bone57,58. 
Even if sufficient numbers of cells can be aspired, concentrated, and re-injected into a defect site, auto-
transplantation strategies still suffer from the same key difficulty as any Tissue Engineering approach 
which uses cell implantation, namely that a population of cells are instantaneously placed into a micro-
environment which has not yet developed the necessary microvasculature, and any cells located more 
than a few hundred micrometres from the nearest blood supply will not receive an adequate nutrient 
supply to survive. In principle however, this problem is avoided using the third possibility for 
endogenous cell recruitment - cell homing. Under the influence of molecular cues, migrating MSCs can 
exit the marrow space, enter the circulation, and migrate to a defect site using cellular adhesion, rolling, 
and transmigration through the epithelium34,59 in an analogous manner to the more well defined 
leukocyte transport mechanisms60. Or progenitor cells already existing in joint tissues can be 
mobilised55,56,61. Tissue niche progenitor cells have even been reported in large avascular structures such 
as the intervertebral disc. Risbud et al62 analysed cells from intervertebral disc samples of five patients 
with degenerate discs as well as adult rat lumbar spine cells, and found that the degenerate human disc 
                                                            
aWe note that this is not strictly auto-transplantation, because the marrow is not removed and re-implanted, but 
the microfracture technique is mentioned here for completeness since it is closely related to marrow auto-
transplantation approaches as a method for inducing localised marrow transport.  
contained populations of skeletal progenitor cells which the authors suggested could be used to 
orchestrate the repair of the intervertebral disc. Cell homing strategies exhibit exciting potential to 
utilise a patient’s existing progenitor cells, however to the extent that they rely on recruitment of bone 
marrow progenitors through the bloodstream, defects in poorly vascularised tissues such as cartilage 
and intervertebral disc may prove problematic and require a focus on signalling stem cells in the 
surrounding tissues rather than trafficking via the bloodstream. With regard to poorly vascularised 
tissues, we note the recent pilot study by Brown et al63 in which fibrocartilage of the canine 
temporomandibular joint meniscus was regenerated using a porcine urinary bladder extracellular matrix 
scaffold, which acted as an inductive template for cell infiltration and new matrix formation. 
 
Molecular signalling 
Whichever approach is used to locate endogenous cells at the defect site, appropriate modulation of 
cellular activity to induce tissue regeneration is critical. Since the initial discovery of nerve growth 
stimulating factor in 195464, a large body of research has explored the spatiotemporal characteristics of 
autocrine and paracrine cell signalling via growth factors during wound healing, and attempts have been 
made to mimic the healing cascade through the controlled administration of growth factors. Growth 
factors are polypeptide molecules that bind to membrane-bound receptors35, and those involved in 
musculoskeletal tissue regeneration include; vascular epithelial growth factor (VEGF) which plays a key 
role in angiogenesis, transforming growth factor beta (TGF- which is involved in thrombogenesis 
during wound healing and is also a potent inhibitor of epithelial cell proliferation, bone morphogenetic 
protein (BMP), especially BMP-2 and BMP-7 which are important for bone formation, epithelial growth 
factor (EGF) which is responsible for proliferation of epithelial cells, platelet derived growth factor (PDGF) 
which modulates growth of mesenchymal cells (thrombocytes release large amounts of PDGF for the 
initiation of thrombogenesis in wound healing), and fibroblast growth factor (FGF) which is a ubiquitous 
factor in the musculoskeletal system controlling growth & survival of fibroblasts, chondrocytes, 
osteoblasts and smooth muscle cells. 
A key challenge in endogenous regeneration is the controlled spatiotemporal delivery of these 
molecular cues at a regeneration site65. The majority of TE studies involving growth factor delivery to 
date have administered a single growth factor, and the growth factors currently in clinical use (e.g. BMP-
2 and BMP-7) are often delivered in a single supra-physiological dose which is dissipated shortly after 
delivery. This single dose, single factor approach is a gross approximation to the tightly controlled 
sustained delivery of multiple growth factors which occurs in endogenous wound healing, and a recent 
paper by Chen et al66 has reviewed more sophisticated attempts to deliver two or more growth factors 
in a controlled manner. 
Parekkadan et al67 recently re-conceptualised the role of MSCs in repair and regeneration by suggesting 
that MSCs promote regeneration by acting as molecular cues at a defect site, rather than engraftment 
and proliferation themselves. This reductionist approach (i.e. MSCs are effectively molecular 
therapeutics) is attractive in principle, because it suggests that if MSCs essentially act as molecular cues, 
their role could be recapitulated by an appropriately designed system of synthetic biochemical cues. 
However the replacement of a closed loop signalling system in which MSCs both sense and signal their 
environment, with an open loop system in which MSC-mimicking cues are released in a pre-determined 
fashion risks losing the tightly integrated control exhibited by MSCs as trophic mediators68. 
Role of the scaffold in endogenous TE 
We have so far discussed sources of endogenous cells and the importance of signalling molecules in 
biochemical modulation of cell behaviour. What is the role of the scaffold in endogenous regeneration? 
Here we conceptualise the scaffold as a bi-domain cell signalling device, which provides both 
biochemical and biophysical cues to endogenous cells by acting as;  
(i) a vector for encapsulation and controlled delivery of signalling molecules to modulate the 
regeneration process, and, 
(ii) a deformable porous structure providing biophysical (substrate strain and interstitial fluid flow) 
cues for migration, attachment, proliferation, angiogenesis and patterned tissue formation 
by cells in the vicinity of the defect site. 
With respect to the scaffold’s role in delivery of biochemical cues, numerous approaches for controlled 
spatiotemporal release of signalling molecules are currently under development66. As one example, 
hepatocyte growth factor (HPC) is a powerful chemoattractant to MSCs, however it is rapidly 
proteolysed in vivo, so strategies to deliver a sustained release of HPC by encapsulation in a semi-
synthetic ECM-like hydrogel are under development69. As another example, in exploring the inductive 
potential of scaffolds composed of decellularised ECM, Badylak’s group have recently documented the 
progenitor cell recruitment potential of a single cryptic peptide derived from the  subunit of the 
collagen III molecule70. To this end, future research efforts specifically targeted at C2 endogenous TE 
strategies (see Table 2) should focus on incorporation and controlled release of cues to attract bone 
marrow and tissue niche precursor cells via cell homing. If C3 strategies prove viable in musculoskeletal 
tissues, scaffold research efforts could focus on controlled signalling to promote de-differentiation, 
proliferation, and re-differentiation of endogenous cells. An alternative conception of the scaffold as a 
biochemical signalling device is reviewed by Evans et al, in which the scaffold is conceived as a ‘gene 
activated matrix’ such that a scaffold impregnated with plasmid DNA transfects endogenous progenitor 
cells which then express the desired gene32. 
With respect to the scaffold’s role as a biophysical signalling device, the scaffold plays a complex 
mechanical role which requires it to provide a degree of structural support to the neighbouring ECM in a 
load-bearing musculoskeletal tissue, while at the same time providing appropriate micro-scale signals to 
cells through substrate strain and interstitial fluid flow, and also degrading in a controlled manner for 
creeping substitution by newly forming tissue. This requirement for mechanical integrity is a major 
challenge in musculoskeletal applications of TE, and a wide range of biomaterials and fabrication 
techniques are currently under development. Macro-scale assessments of scaffold integrity are often 
limited to basic quasi-static compression tests, and in many cases no attempt is made to define or 
design the biophysical micro-environment experienced by cells in the scaffold from the perspective of 
substrate strain, interstitial fluid flow, or oxygen diffusion71. There is much potential for improved, 
quantitative biophysical assessment of the cellular environment in and around scaffolds72, and a small 
body of studies using structural analysis techniques such as the Finite Element Method provide a 
valuable starting point in this regard73-77. An improved understanding of scaffold biophysical signalling is 
essential for the viable development of endogenous TE strategies, since whether cells are auto-
transplanted, attracted via homing, or de-differentiated, the biomechanical micro-environment must 
promote cell viability and new tissue growth. In addition to biomechanical aspects (solid deformation 
and fluid flow), the generation of endogenous electric fields may be an important but thus far little 
considered topic in scaffold biophysics, as it is known that endogenous electric fields play an important 
role in guiding native tissue growth during both development and regeneration78-81. 
While developments in scaffold research for endogenous TE would be expected to parallel those for use 
with exogenous or cultured cells to some extent, in an endogenous strategy the scaffold may be 
promoting quite different cellular processes (homing or even de-differentiation) and so future scaffold 
designs for biochemical and biophysical signalling in endogenous TE may diverge from those used for 
cultured autologous or exogenous cells. Chen et al34 provide an excellent discussion of bioscaffold 
considerations for cell homing. The overarching philosophy is that the scaffold acts as an artificial ECM 
which modulates cellular activity and enhances the body’s innate regenerative potential82. Note that the 
term ‘artificial’ is used here in contrast to the functioning native tissue ECM at the regeneration site, and 
does not preclude the use of ‘natural’ ECM from other sources as the scaffold material83. Figure 1 shows 
a schematic realisation of this philosophy, in which a scaffold encapsulating growth factors provides 
both biophysical and biochemical cues to direct stem cell activity through one of the three possible 
endogenous strategies.    
 
             
Figure 1. Schematic showing three potential endogenous Tissue Engineering strategies for regeneration of an 
osteochondral defect: C1:Auto-transplantation of progenitor cells, C2: Stem cell homing from bone marrow via 
bloodstream and from tissue niche, C3: De-differentiation of previously committed cells . In each case, the scaffold 
is a biophysical and biochemical signalling source to modulate the regenerative process. 
 
Toward clinical impact 
What clinical impact have endogenous TE approaches had to date? Ingber et al84 give a compelling 
overview of the challenges which have hindered attempts at clinical translation of TE to date. However, 
there have also been successes. Firstly, there are several ‘traditional’ orthopaedic surgical techniques 
which are essentially endogenous TE approaches, even if not named as such. Long bone fracture repair, 
in which autologous bone graft is placed in the defect site, is a clinically proven technique in which auto-
transplanted autologous bone promotes successful fracture healing. Similarly, distraction osteogenesis 
achieves rapid bone formation without the use of exogenous cells, scaffolds or growth factors through 
the application of a mechanical strain signal to the native tissue ECM. Both of these orthopaedic 
interventions are separately covered in another paper in this special edition (Berner et al). Another 
widely used orthopaedic procedure involves fusing of two adjacent vertebrae in the spine to treat joint 
pain or instability. Spine fusion is also effectively an endogenous TE strategy, in which the joint is held 
immobile with an implant (after intervertebral disc removal), and new bone formation by endogenous 
cells is encouraged through grafting with a biomaterial scaffold and application of growth factors to fuse 
the joint space. 
Although these orthopaedic procedures are effectively endogenous TE strategies, there are  significant 
problems with autologous bone grafting with regard to donor site morbidity and availability. In the case 
of large bone defects, sufficient quantities of autologous bone may not be available. Furthermore, 
defects in other musculoskeletal tissues (ligaments, skeletal muscle, tendon, cartilage and intervertebral 
disc) do not generally have a source of autogenous tissue available for use as a scaffold, therefore 
synthetic scaffolds are required. An example of successful spine fusion using a synthetic scaffold is given 
by Abbah et al85 who used 15x12x4mm3 porous scaffolds to successfully induce lumbar interbody spinal 
fusion in a pig study. The scaffolds were 70% porosity with 100% pore interconnectivity and 350-500m 
pore size, composed of 80% polycaprolactone (PCL) and 20%  -tricalcium phosphate (TCP). Prior to 
implantation the scaffolds were impregnated with recombinant human bone morphogenetic protein-2 
(rhBMP-2). Compared to a control group which received autogenous bone graft in the excised disc space, 
the scaffold+rhBMP-2 group showed greater bone formation earlier than in the control group. This 
study demonstrates that rapid bony fusion is possible in the spine using a synthetic scaffold and growth 
factor combination without cell transplantation. 
One of the most promising studies to date in terms of demonstrating the potential of endogenous TE 
strategies for large scale complex musculoskeletal defect regeneration is that of Lee et al28, who 
successfully regenerated the entire articular surface of the rabbit synovial joint using a composite (80% 
polycaprolactone and 20% hydroxyapatite) scaffold, impregnated with TGF3 growth factor absorbed in 
a collagen hydrogel. A 12x10x17mm3 scaffold of pore size 200-400m was used, and the authors noted 
that endogenous cell recruitment rather than transplantation was a key factor in their approach, 
modulated by providing an appropriate biological cue in an anatomically correct bio-scaffold. The 
authors noted that a similar study which did not use growth factors was unsuccessful86. Taken together, 
these two studies again highlight the importance of appropriate molecular signalling for successful 
regeneration. 
Another approach which appears to have achieved a degree of clinical success in regeneration of 
musculoskeletal defects is so-called ‘Endoret’ (endogenous regenerative technology) which focuses on 
the use of autologous platelets encapsulated within autologous fibrin scaffolds31,87,88. Anitua et al 
reported extensive bone regeneration using Endoret in twenty patients who underwent tooth extraction 
for fractures or periodontal disease89. Another study comparing Endoret with controls for bilateral sinus 
floor augmentation in a series of five patients reported typical findings of 20-30% new bone formation in 
the treated area versus 8% new bone formation in the control area. Based on immunohistochemical 
analysis, the authors reported 116 blood vessels per mm2 in the treated area, compared with only 7 per 
mm2 in the control area90. 
 Summary and Conclusions  
Endogenous regeneration of the musculoskeletal system is a potentially attractive alternative to other 
Tissue Engineering strategies requiring ex vivo cell culture or implantation of exogenous cells. Whilst 
several widely used orthopaedic procedures are effectively endogenous TE approaches because they 
regenerate defects without cell implantation, endogenous TE is still a nascent research field because 
relatively little is known about the molecular signalling processes governing endogenous cell homing 
from marrow and tissue niches, the de-differentiation potential of mammalian musculoskeletal cells is 
unknown, and critical sized defects in musculoskeletal tissues often do not have a sufficient source of 
autologous graft tissue.  
Endogenous cell homing strategies using the ‘body as bioreactor’ approach have the advantage of 
attracting cells to a defect site because the microenvironment and blood supply are conducive to 
regeneration, rather than implantation of cells into a scaffold where their nutrient status and viability is 
uncertain. Several recent studies have demonstrated the capability of cell homing approaches with 
synthetic scaffolds to regenerate large defects in musculoskeletal tissues, and further investigation in 
this field is strongly warranted. 
The scaffold is a crucial component in designing Tissue Engineering constructs for load-bearing 
musculoskeletal applications, and in endogenous strategies the scaffold should be considered as both a 
biochemical and biophysical signalling device, modulating and orchestrating cellular activity in the 
defect microenvironment to harness and direct a patient’s own regenerative potential. There are many 
challenges in furthering this concept, firstly in developing a proper understanding of the native 
regenerative capacity of musculoskeletal organs and tissues, and then in engineering clinically feasible 
interventions to optimise this capacity. 
________________________________________ 
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